Description
SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC50 of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).
SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC50 of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).
B3218 | SB1317 (TG-02) DataSheet
Alternate Name/Synonyms: (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene,Zotiraciclib
Appearance: Crystalline solid
Formulation:
CAS Number: 1204918-72-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₃H₂₄N₄O
Molecular Weight: 372.46
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: >20 mg/ml DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A potent inhibitor of CDK2, JAK2, and FLT3
MDL Number:
PubChem CID: 16739650
SMILES: CN1CC=CCCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
InChi: InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+
InChi Key: VXBAJLGYBMTJCY-NSCUHMNNSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |